Journal
AMERICAN JOURNAL OF PSYCHIATRY
Volume 173, Issue 11, Pages 1110-1118Publisher
AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.2016.16010118
Keywords
-
Categories
Funding
- NIMH [U01MH055495, U01MH081362, U01MH086127, U01MH086130, U01MH08612005, U01MH084241, U01MH086122]
- Alkermes
- Assurex
- Avanir
- Cyberonics
- Brainsway
- MagStim
- NARSAD
- National Institute of Neurological Disorders and Stroke
- National Institute on Aging
- NeoSync
- Neuronetics
- NIDA
- NIMH
- Stanley Foundation
- St. Jude Medical (Advanced Neuromodulation Systems)
- American Foundation for the Prevention of Suicide
- Amgen
- AstraZeneca
- Corcept
- Eli Lilly
- Proteus
- St. Jude Medical
- Sunovion
- Brain and Behavior Research Foundation
- Stanley Medical Research Foundation
- Nexstim
- NIH
Ask authors/readers for more resources
Objective: The randomized phase (phase 2) of the Prolonging Remission in Depressed Elderly (PRIDE) study evaluated the efficacy and tolerability of continuation ECT plus medication compared with medication alone in depressed geriatric patients after a successful course of ECT (phase 1). Method: PRIDE was a two-phase multisite study. Phase 1 was an acute course of right unilateral ultrabrief pulse ECT, augmented with venlafaxine. Phase 2 compared two randomized treatment arms: a medication only arm (venlafaxine plus lithium, over 24 weeks) and an ECT plus medication arm (four continuation ECTtreatments over1 month, plus additional ECT as needed, using the Symptom-Titrated, Algorithm-Based Longitudinal ECT [STABLE] algorithm, while continuing yenlafaxine plus lithium). The intent-to-treat sample comprised 120 remitters from phase 1. The primary efficacy outcome measure was score on the 24-item Hamilton Depression Rating Scale (HAM-D), and the secondary efficacy outcome was score on the Clinical Global Impressions severity scale (CGI-S). Tolerability as measured by neurocognitive performance (reported elsewhere) was assessed using an extensive test battery; global cognitive functioning as assessed by the Mini-Mental State Examination (MMSE) is reported here. Longitudinal mixed-effects repeated-measures modeling was used to compare ECT plus medication and medication alone for efficacy and global cognitive function outcomes. Results: At 24 weeks, the ECT plus medication group had statistically significantly lower HAM-D scores than the medication only group. The difference in adjusted mean HAM-D scores at study end was 4.2 (95% CI = 1.6, 6.9). Significantly more patients in the ECT plus medication group were rated not ill at all on the CGI-S compared with the medication only group. There was no statistically significant difference between groups in MMSE score. Conclusions: Additional ECT after remission (here operationalized as four continuation ECT treatments followed by further ECT only as needed) was beneficial in sustaining mood improvement for most patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available